Our strategy is to be known as âthe prostate cancer companyâ. We aspire to be disease focused by providing a âcontinuum of careâ for prostate cancer patients. Prostate cancer is becoming a chronic disease with new challenges as prostate cancer develops resistance to current drugs and progresses and as the patient suffers from the long-term side effects of these treatments like bone loss and fractures, hot flashes, loss of libido and erectile dysfunction, loss of muscle strength and frailty. Accordingly, we are dedicated to the development and commercialization of products to address unmet medical needs for prostate cancer treatment and supportive care. Given our core expertise and the number and type of drugs in our pipeline, we are uniquely positioned to understand, develop, and commercialize medicines for these unmet medical needs of prostate cancer patients. Source
No articles found.
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on deve...
Aptevo Therapeutics Inc. is a clinical-stage bi...
At Bellerophon Therapeutics, we aim to transform the lives of people suffering fro...
At Bellerophon Therapeutics, we aim to transfor...
We are a global frontrunner in making oral vaccines a reality. Weâve created a p...
We are a global frontrunner in making oral vacc...
We are an innovative biopharmaceutical company developing therapies to treat the m...
We are an innovative biopharmaceutical company ...
Acer is a pharmaceutical company focused on the acquisition, development and comme...
Acer is a pharmaceutical company focused on the...
Join the National Investor Network and get the latest information with your interests in mind.